Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of hepatic arterial infusion of cultured autologous bone marrow-derived mesenchymal stem cells in decompensated liver cirrhosis (BMSC-Hai)
jRCTb060190035Completed
- Sponsor
- Shibuya Corporation
- Start
- Jul 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous bone marrow derived mesenchymal stromal cells in Cirrhosis, sponsored by Shibuya Corporation. Primary endpoint: Incidence of adverse events. Started Jul 2019; status: completed.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on jRCTb060190035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTb060190035.